Publications
Activity-based proteomics discovery of deubiquitinating enzyme inhibitors with immunomodulatory activity.
Jones HBL. et al, (2026), NPJ Drug Discov, 3
Selective USP32 inhibition reveals endosomal ubiquitin signaling and enables cell-permeable activity-based probes.
Scherpe S. et al, (2026), Cell Chem Biol
SHIP1 regulates TREM2 signalling and macrophage functions in a hiPSC-derived model.
Martin KS. et al, (2026), FEBS J
The autosomal deubiquitylase Trabid drives sex-divergent neurodegeneration in Drosophila
Xia J. et al, (2026), Communications Biology
DHODH is the key target of the KDM4 inhibitor QC6352 in glioblastoma stem cells.
Sterling JR. et al, (2026), Nat Chem Biol
The changing face of UK academic drug screening in the past decade.
Baronio R. and Ebner D., (2026), Nat Rev Drug Discov, 25, 809 - 810
Ubiquitin chain editing promotes p97/VCP-dependent removal of RPA from DNA.
Drake M. et al, (2026), Mol Cell, 86, 3897 - 3914.e18
Structures of the human sodium-citrate cotransporter NaCT with and without substrates.
Sauer DB. et al, (2026), Structure, 34, 1405 - 1413.e2
Cross-Ancestry Proteogenomic Analyses Identified New Therapeutic Insights for Ischemic Heart Disease.
Mazidi M. et al, (2026), J Am Coll Cardiol, 88, 1107 - 1120